Summary
Malaria is endemic in Guinea, however, the extent and role in transmission of asymptomatic malaria are not well understood. In May 2023, we conducted a rapid community survey to determine Plasmodium falciparum prevalence among asymptomatic individuals in Middle Guinea (Dalaba) and Forest Guinea (Guéckédou). We used a cluster sampling approach with purposive selection of two prefectures and four communities and full enrolment of all individuals in the selected communities. Prevalence was calculated with a 95% confidence interval (CI). In Dalaba, 6/239 (2.1%, CI 0.9-4.8%) individuals tested positive for P. falciparum by rapid diagnostic test, while in Guéckédou, 147/235 (60.9%, CI 54.5-66.9%) of participants tested positive. Asymptomatic malaria needs to be considered more strongly as a driver for transmission when designing control strategies, especially in Forest Guinea and potentially other hyper-endemic settings.
Key results and their importance
Prevalence of asymptomatic malaria was very high (60.9%, CI 54.5-66.9%) in the selected communities in Forest Guinea.
Prevalence was expectedly low (2.1%, CI 0.9-4.8%) in the selected communities in Middle Guinea.
Current control strategies in Forest Guinea seem insufficient to reduce malaria prevalence, and likely also transmission.
Both policies and control strategies need to more proactively consider asymptomatic malaria in hyper-endemic settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by a Defense Threat Reduction Agency (DTRA) grant (grant number: HDTRA12110028).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Georgetown University gave ethical approval for this work (STUDY00002481) and the Comite National D Ethique Pour la Recherche en Sante (CNERS) of the Republic of Guinea gave ethical approval of this work (040/CNERS/2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* ch950{at}cam.ac.uk, Claire.Standley{at}georgetown.edu
Additions to analysis with age-disaggregation of prevalences, fixing minor mistakes and clarification of language
Data Availability
Due to the very small number of respondents in some age and gender (other) categories, the data cannot be made publicly available as they are potentially identifying.